Annexon has announced enrollment is complete for the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company said in a press release that it remains on track to report topline data in the second half of 2026.

According to Annexon, vonaprument is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. The neuroprotective effect and consistent benefits of C1q inhibition were previously demonstrated by vonaprument in the phase 2 ARCHER trial. Vonaprument is the only investigational therapy, according to the company, for dry AMD with GA to show significant vision preservation based upon best-corrected visual acuity (BCVA) and low-luminance visual acuity (LLVA). 

ARCHER II is a global, randomized, double-masked, sham-controlled pivotal trial designed to assess both visual acuity and structural measures to satisfy the global registration path in the United States and Europe. Vonaprument has received Priority Medicine (PRIME) designation in Europe and fast track designation in the United States. RP